Overcoming mutation-based resistance to antiandrogens with rational drug design.
Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL. · 2013
Read Overcoming mutation-based resistance to antiandrogens with rational drug design. by Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3622181.txt.
Description
Minna Balbas and colleagues hunted in advance for ways prostate cancer escapes a new drug, in eLife in 2013. Enzalutamide, a second-generation hormone blocker, had just been approved for castration-resistant prostate cancer, but responses often fade. For older blockers, one escape was mutation of the androgen receptor, the protein the drugs jam. The team deliberately mutated the receptor in a screening system to find changes that defeat the drug before clinics met them.
One change, F876L, did worse than defeat the drug: it turned enzalutamide into a receptor activator, and cells carrying it grew through treatment. Computer simulations of the mutant complex showed the switch reshaping a key helix, explaining the flip. That model then directed a search over existing blocker scaffolds, which found three fresh compounds that shut down both mutant and normal receptors. Advance scouting of resistance is the paper's strategy.
Catalog record
| CREATOR | Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL. |
|---|---|
| YEAR | 2013 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 70 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |